SVB Wealth LLC Has $4.04 Million Stake in Abbott Laboratories $ABT

SVB Wealth LLC lowered its holdings in Abbott Laboratories (NYSE:ABT) by 14.5% in the second quarter, HoldingsChannel.com reports. The firm owned 44,462 shares of the healthcare product maker’s stock after selling 7,515 shares during the quarter. SVB Wealth LLC’s holdings in Abbott Laboratories were worth $4,035,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Cornerstone Financial Management LLC bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories during the 4th quarter worth $25,000. Purpose Unlimited Inc. acquired a new position in Abbott Laboratories in the 4th quarter valued at $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $26,000. Finally, Abound Financial LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $26,000. 75.18% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on ABT shares. JPMorgan Chase & Co. raised their price target on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Wolfe Research raised shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective for the company in a research report on Thursday, August 13th. Citigroup increased their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Robert W. Baird initiated coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price for the company. Finally, UBS Group cut their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $119.50.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $105.66 on Wednesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The stock has a market capitalization of $182.82 billion, a P/E ratio of 34.19, a price-to-earnings-growth ratio of 2.01 and a beta of 0.59. The stock has a fifty day moving average of $105.04 and a 200-day moving average of $99.95.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same period last year, the firm posted $1.26 earnings per share. Abbott Laboratories’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.